Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 3NIH 1FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2875Carcinoma, Non-Small-Cell Lung 2428Breast Neoplasms 2068Colorectal Neoplasms 1247Neoplasm Metastasis 1232Prostatic Neoplasms 1080Melanoma 974Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 852Leukemia, Myeloid, Acute 810Lung Neoplasms 758Pancreatic Neoplasms 753Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 623Carcinoma, Hepatocellular 566Carcinoma, Renal Cell 546Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 451Glioblastoma 436Advanced Solid Tumors 432Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 410Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

Vaccines 3Herpes Zoster Vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Herpes Zoster × Clear all
NCT01798056 2021-05-13

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

GlaxoSmithKline

Phase 3 Completed
237 enrolled 20 charts

Herpes Zoster

NCT01254630 2019-09-30

V212-011

Merck Sharp & Dohme LLC

Phase 3 Completed
5,305 enrolled 20 charts
Other hematologic neoplasm

Herpes Zoster, Hematologic Neoplasms

NCT01460719 2019-03-11

V212-013

Merck Sharp & Dohme LLC

Phase 1 Completed
80 enrolled 13 charts

Herpes Zoster

NCT01767467 2018-06-06

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

GlaxoSmithKline

Phase 3 Completed
568 enrolled 26 charts

Herpes Zoster

Data powered by HemOnc (CC BY 4.0) Colophon âš¡